Moore DC - Search Results

1

Fostamatinib for the treatment of immune thrombocytopenia in adults.

Moore DC, Gebru T, Muslimani A. Moore DC, et al. Am J Health Syst Pharm. 2019 May 17;76(11):789-794. doi: 10.1093/ajhp/zxz052. Am J Health Syst Pharm. 2019. PMID: 30951590

2

Necitumumab for the treatment of squamous cell non-small cell lung cancer.

Brinkmeyer JK, Moore DC. Brinkmeyer JK, et al. Among authors: moore dc. J Oncol Pharm Pract. 2018 Jan;24(1):37-41. doi: 10.1177/1078155216682365. Epub 2016 Dec 2. J Oncol Pharm Pract. 2018. PMID: 27913776 Review.

3

Nilotinib-Induced Ocular Toxicity: A Case Report.

Moore DC, Muslimani A, Sinclair P. Moore DC, et al. Am J Ther. 2018 Sep/Oct;25(5):e570-e571. doi: 10.1097/MJT.0000000000000650. Am J Ther. 2018. PMID: 28806182 No abstract available.

4

Rucaparib: A Poly(ADP-Ribose) Polymerase Inhibitor for BRCA-Mutated Relapsed Ovarian Cancer.

Moore DC, Ringley JT, Patel J. Moore DC, et al. J Pharm Pract. 2019 Apr;32(2):219-224. doi: 10.1177/0897190017743131. Epub 2017 Nov 22. J Pharm Pract. 2019. PMID: 29166829 Review.

5

Metastatic Soft Tissue Sarcomas: A Review Of Treatment and New Pharmacotherapies.

Singhi EK, Moore DC, Muslimani A. Singhi EK, et al. Among authors: moore dc. P T. 2018 Jul;43(7):410-429. P T. 2018. PMID: 30013298 Free PMC article.

6

Transitioning historically inpatient chemotherapy regimens for hematologic malignancies to the ambulatory care setting.

Moore DC, Arnall JR, Plesca DC. Moore DC, et al. Am J Health Syst Pharm. 2018 Nov 15;75(22):1824-1830. doi: 10.2146/ajhp180060. Epub 2018 Aug 21. Am J Health Syst Pharm. 2018. PMID: 30131323 No abstract available.

7

Neutropenia-Associated Outcomes in Patients With Breast Cancer Receiving Myelosuppressive Chemotherapy With Reduced Doses of Pegfilgrastim.

Moore DC, Gebru T, Pellegrino A, Fasan A, Patel J, Ringley JT. Moore DC, et al. J Pharm Pract. 2020 Dec;33(6):779-783. doi: 10.1177/0897190019838374. Epub 2019 Mar 27. J Pharm Pract. 2020. PMID: 30917723

8

Impact of Body Mass Index on the Incidence of Bortezomib-induced Peripheral Neuropathy in Patients With Newly Diagnosed Multiple Myeloma.

Moore DC, Ringley JT, Nix D, Muslimani A. Moore DC, et al. Clin Lymphoma Myeloma Leuk. 2020 Mar;20(3):168-173. doi: 10.1016/j.clml.2019.08.012. Epub 2019 Sep 18. Clin Lymphoma Myeloma Leuk. 2020. PMID: 32029398

9

Caplacizumab: an anti-von Willebrand factor antibody for the treatment of thrombotic thrombocytopenic purpura.

Hollifield AL, Arnall JR, Moore DC. Hollifield AL, et al. Among authors: moore dc. Am J Health Syst Pharm. 2020 Jul 23;77(15):1201-1207. doi: 10.1093/ajhp/zxaa151. Am J Health Syst Pharm. 2020. PMID: 32588878 Review.

10

Successful treatment with enasidenib, bortezomib, and dexamethasone for the synchronous occurrence of IDH2-positive acute myeloid leukemia and multiple myeloma.

Moore DC, Nelson V, Muslimani A. Moore DC, et al. Ann Hematol. 2021 Dec;100(12):3053-3055. doi: 10.1007/s00277-020-04285-y. Epub 2020 Oct 1. Ann Hematol. 2021. PMID: 33001279 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

457 results

Search Page

Filters